Actuate Therapeutics

Actuate has no recurring revenue and depends on clinical, regulatory, and financing milestones. While the Phase 2 PDAC result is encouraging and peer‑reviewed, the company must still align with regulators on a registrational strategy and execute at scale. Oral elraglusib introduces additional formulation and dose‑exposure risks.

Competitive dynamics and payer responses further reduce visibility. This profile does not meet our preference for steady, recurring, and geographically diversified cash flows.